Marcelo Bigal, MD, PhD

Dr. Bigal discusses the findings from two phase IIb clinical trials of TEV-48125, a CGRP monoclonal antibody, for the preventive treatment of chronic migraine and for high-frequency episodic migraine.



The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Next Article: